Assessment of primary prevention patients receiving an ICD - Systematic evaluation of ATP: APPRAISE ATP.

ICD Primary prevention VT

Journal

Heart rhythm O2
ISSN: 2666-5018
Titre abrégé: Heart Rhythm O2
Pays: United States
ID NLM: 101768511

Informations de publication

Date de publication:
Aug 2021
Historique:
entrez: 25 8 2021
pubmed: 26 8 2021
medline: 26 8 2021
Statut: epublish

Résumé

The value of antitachycardia pacing (ATP) in the overall cohort of primary prevention patients who receive implantable cardioverter-defibrillators (ICDs) remains uncertain. ATP success reported in prior trials potentially included a large number of patients receiving unnecessary ATP for arrhythmias that may have self-terminated owing to the prematurity of the intervention. Although some patients derive benefit from initial ATP in terminating rapid ventricular arrhythmias and thereby preventing shocks, there are limited data allowing us to identify those patients The purpose of APPRAISE ATP is to understand the role of ATP in primary prevention patients currently indicated for ICD therapy in a large prospective randomized controlled trial with modern programming parameters. The study is a global, prospective, randomized, multicenter clinical trial conducted at up to 150 sites globally, enrolling approximately 2600 subjects The primary endpoint of the trial is An Electrogram and Device Interrogation Core Laboratory will review interrogation data to determine primary endpoints that occur in APPRAISE ATP. Their decisions are based on independent physician review of the data from device interrogation. The ultimate purpose of the study is to aid clinicians in the selection of ICD technologies based on hard endpoint evidence across the spectrum of indications for primary prevention implantation.

Sections du résumé

BACKGROUND BACKGROUND
The value of antitachycardia pacing (ATP) in the overall cohort of primary prevention patients who receive implantable cardioverter-defibrillators (ICDs) remains uncertain. ATP success reported in prior trials potentially included a large number of patients receiving unnecessary ATP for arrhythmias that may have self-terminated owing to the prematurity of the intervention. Although some patients derive benefit from initial ATP in terminating rapid ventricular arrhythmias and thereby preventing shocks, there are limited data allowing us to identify those patients
OBJECTIVE OBJECTIVE
The purpose of APPRAISE ATP is to understand the role of ATP in primary prevention patients currently indicated for ICD therapy in a large prospective randomized controlled trial with modern programming parameters.
METHODS METHODS
The study is a global, prospective, randomized, multicenter clinical trial conducted at up to 150 sites globally, enrolling approximately 2600 subjects The primary endpoint of the trial is
RESULTS RESULTS
An Electrogram and Device Interrogation Core Laboratory will review interrogation data to determine primary endpoints that occur in APPRAISE ATP. Their decisions are based on independent physician review of the data from device interrogation.
CONCLUSION CONCLUSIONS
The ultimate purpose of the study is to aid clinicians in the selection of ICD technologies based on hard endpoint evidence across the spectrum of indications for primary prevention implantation.

Identifiants

pubmed: 34430946
doi: 10.1016/j.hroo.2021.07.003
pii: S2666-5018(21)00120-3
pmc: PMC8369290
doi:

Types de publication

Journal Article

Langues

eng

Pagination

405-411

Informations de copyright

© 2021 Heart Rhythm Society. Published by Elsevier Inc.

Références

Circ Arrhythm Electrophysiol. 2014 Oct;7(5):785-92
pubmed: 25136077
N Engl J Med. 2012 Dec 13;367(24):2275-83
pubmed: 23131066
N Engl J Med. 1996 Dec 26;335(26):1933-40
pubmed: 8960472
J Am Coll Cardiol. 2008 Apr 8;51(14):1357-65
pubmed: 18387436
Heart Rhythm. 2020 Jan;17(1):e220-e228
pubmed: 31103461
Heart Rhythm. 2016 Feb;13(2):e50-86
pubmed: 26607062
JAMA. 2013 May 8;309(18):1903-11
pubmed: 23652522
N Engl J Med. 2005 Jan 20;352(3):225-37
pubmed: 15659722
N Engl J Med. 2002 Mar 21;346(12):877-83
pubmed: 11907286
Circulation. 2004 Oct 26;110(17):2591-6
pubmed: 15492306
Circulation. 2001 Aug 14;104(7):796-801
pubmed: 11502705
N Engl J Med. 2008 Sep 4;359(10):1009-17
pubmed: 18768944
Pacing Clin Electrophysiol. 1993 Mar;16(3 Pt 2):535-9
pubmed: 7681953
J Am Coll Cardiol. 2011 Feb 1;57(5):556-62
pubmed: 21272746
J Am Coll Cardiol. 2013 Mar 26;61(12):1318-68
pubmed: 23453819
J Am Coll Cardiol. 2008 Aug 12;52(7):541-50
pubmed: 18687248
Heart Rhythm. 2021 Mar;18(3):399-403
pubmed: 33232811

Auteurs

Claudio D Schuger (CD)

Henry Ford Heart & Vascular Institute, Detroit, Michigan.

Kenji Ando (K)

Kokura Memorial Hospital, Kitakyushu, Japan.

Daniel J Cantillon (DJ)

Cleveland Clinic, Heart and Vascular Institute, Cardiac Electrophysiology and Pacing, Cleveland, Ohio.

Pier D Lambiase (PD)

St. Bartholomew's Hospital, London, United Kingdom.

Lluis Mont (L)

Department of Cardiology, Hospital Clinic, University of Barcelona, Barcelona, Spain.

Bo Young Joung (BY)

Yonsei University Severance Hospital, Seoul, Korea.

Darren Peress (D)

Pima Heart Physicians, PC, Tucson, Arizona.

Patrick Yong (P)

Boston Scientific Corporation, St. Paul, Minnesota.

Nicholas Wold (N)

Boston Scientific Corporation, St. Paul, Minnesota.

James P Daubert (JP)

Duke University Medical Center, Durham, North Carolina.

Classifications MeSH